AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06322719 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh blade videolaryngoscope
Description: For patients assigned to the Macintosh videolaryngoscope Group, the operator will use a Hyperangulated video laryngoscope on the first laryngoscopy attempt.
Study NCT05492630 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HEC73077 tablets
Description: Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Study NCT05471713 — intervention group
Intervention type: OTHER
Intervention: Autonomic dysfunction
Description: Autonomic dysfunction
Study NCT05492630 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: HEC73077 placebo tablets
Description: Single-Dose Study: Each dose of HEC73077 and placebo will be administered with approximately 240 mL of water in the morning after fasting for at least 10 hours overnight.~Multiple-dose study:The study doses, administration method (fasted or fed), dosing frequency, and dosing period are all to be determined based on data from the single-dose study and/or multiple-dose study.
Study NCT05792774 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain
Description: The experimental intervention will consist of ultrasound-guided anesthetic blockade of the phrenic nerve at the laterocervical supraclavicular level with 1 ml of lidocaine without vasoconstrictor 2% to infiltrate the skin and 3ml of bupivacaine without vasoconstrictor 0.25% for neural blockade, making the local anesthetic surround the nerve between the anterior scalene muscle and the sternocleidomastoid muscle.
Study NCT05792774 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (physiological saline serum infiltration)
Description: The placebo intervention will be similar in relation to 2% lidocaine without vasoconstrictor for the skin, but an ultrasound-guided puncture will be performed at the level of the subcutaneous cellular tissue by injecting 3 ml of physiological saline.
Study NCT04699747 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: F-18 3F4AP
Description: Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).
Study NCT04699747 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: F-18 3F4AP
Description: Subjects will be injected once per imaging session (a maximum of 2 imaging sessions) with up to 10 mCi (±20%) of 18-F 3F4AP as a rapid intravenous bolus (within 1 min).
Study NCT06265922 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High frequency repetitive transcranial magnetic stimulation
Description: High frequency repetitive transcranial magnetic stimulation will be applied over mid line of cerebellum using circular coil. Ten repetition rate (frequency) in 40 trains with one intertrain interval will be applied for three times a week for two weeks.
Study NCT06265922 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham repetitive transcranial magnetic stimulation
Description: Sham repetitive transcranial magnetic stimulation will be applied Perpendicular away from the cerebellum using the same circular coil. The same parameters will be used with the same duration also numbers of sessions are the same like the active comparator group to assure the patients blindness
Study NCT05049226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) full dose
Description: Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 10\^10 viral particles (vp)~\*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle
Study NCT05049226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer/BioNTech BNT162b2 vaccine (PF) full dose
Description: Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle
Study NCT05049226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AstraZeneca ChAdOx1 AZD1222 vaccine (AZ) half dose
Description: Astrazeneca COVID-19 (ChAdOx1 AZD1222) vaccine:~One dose (0.5 ml) contains: COVID-19 Vaccine (ChAdOx1-S\* recombinant) 5 × 10\^10 viral particles (vp)~\*Recombinant, replication-deficient chimpanzee adenovirus vector encoding the SARS-CoV-2 Spike glycoprotein. Produced in genetically modified human embryonic kidney (HEK) 293 cells.~Administer: Intramuscular (IM) injection in the deltoid muscle
Study NCT05049226 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pfizer/BioNTech BNT162b2 vaccine (PF) half dose
Description: Pfizer-BioNTech COVID-19 (BNT162b2) vaccine:~Diluent: 0.9% sodium chloride (normal saline, preservative-free)~Administer: Intramuscular (IM) injection in the deltoid muscle
Study NCT04865523 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manual Lymphatic Drainage
Description: Manual lymphatic drainage is a technique that through gentle passes facilitates the flow of lymph through manual therapy techniques based on Vodder therapy. This technique is being studied to know its effectiveness in pain and for this reason we want to carry out this research.
Study NCT05870982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early TRE
Description: Participants will be instructed to eat only during an 8-hour window starting 1-2 hours after waking.
Study NCT05870982 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Late TRE
Description: Participants will be instructed to eat only during an 8-hour window starting 5-6 hours after waking.
Study NCT05870982 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DCR
Description: Participants will be instructed to reduce caloric intake by 25%.
Study NCT05048550 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Near vision spectacles
Description: Near vision spectacles prescribed for full time wear (Add+3.00DS to the full cycloplegic refraction). These glasses will be changed to reflect changes in refractive error or frame fit as appropriate at follow up.
Study NCT04577157 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mHealth usingWhatsApp multifaceted educational and reminder module intervention to improve adherence
Description: This multifaceted educational and reminder module is named Health@click. The content of the reminder module has been made based on The Health Belief Model and self-determination theory.~1. Daily notes for medication reminders,~2. Daily a voice message with the same content will be delivered.~3. Daily Graphics-based Reminder (GBR).~4. Twice-weekly Graphics-based Messages (GBM) according to Health believe model and Self-determination theory constituents.~5. Once-weekly lifestyle advice through video~6. Hypertension at a glance, complete information will be provided(Optional)~7. 24/7 help provision service will be given to the participants. A qualified doctor will be there to provide this educational support. Support will be including the dose of medicine, frequency, mode of action, effects of medicine on current illness, side effects, and interaction with different foods (Optional).
Study NCT06071728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)
Description: Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.
Study NCT06071728 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572)
Description: Subjects will receive Endocalyx Pro (Microvascular Health Solutions, US Patent Number: 9943572) (3,712mg) or placebo for 12 weeks.
Study NCT03090048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin A
Description: Vitamin A 2-3 % concentration
Study NCT03090048 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin
Description: azithromycin monohydrate
Study NCT03090048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: azithromycin monohydrate
Study NCT05507359 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: clove gel
Description: 4.7% (Pain Out Dental Gel, Colgate Palmolive India Ltd, Solan, India) clove gel
Study NCT05507359 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Benzocaine gel
Description: 20% Benzocaine gel (Opahl gel)
Study NCT05322044 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Financial incentives dependent upon adherence will be given to participants alongside additional EMD associated app features for 12-weeks.
Study NCT06255678 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Angiography-based vessel fractional flow reserve (vFFR) calculation
Description: vFFR is calculated from routinely taken angiography images during PCI using a CAAS workstation (Pie Medical Imaging, Maastricht, the Netherlands)
Study NCT06448416 — intervention group
Intervention type: PROCEDURE
Intervention: UBE
Description: Patients with HDL were treated with UBE
Study NCT04641338 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fixed dose combination Dipyrone and Codeine
Description: Fixed dose combination: dipyrone 1000 mg + codeine 30 mg every 6 hours if necessary.
Study NCT04641338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dipyrone
Description: use of 1000 mg dipyrone every 6 hours if necessary.
Study NCT04641338 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Codeine
Description: 30 mg codeine every 6 hours if necessary.
Study NCT05297630 — intervention group
Intervention type: OTHER
Intervention: Evaluation of the evolution of biological markers from the biobank.
Description: The evolution of sST2, copeptin, chromogranin, NGAL, suPAR and cystatin will be evaluated between Day 0 and Month 1
Study NCT06192979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Daratumumab
Description: Daratumumab 16 mg/kg was administered intravenously weekly in cycles one and two, every two weeks for cycles three to six, for at least 6 cycles.~Daratumumab and hyaluronidase-fihj 1800mg is allowed according to the patients' choice.
Study NCT06192979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bortezomib
Description: All patients received 1.0-1.3 mg/m2 subcutaneous bortezomib once weekly of 28 days each for at 6 cycles.
Study NCT06192979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexamethasone
Description: All patients received 20-40 mg oral or intravenous dexamethasone
Study NCT06192979 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Venetoclax
Description: All patients received venetoclax 400mg daily.
Study NCT05373550 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Effectiveness of a nursing educational intervention on quality of life, sexual function, and self-esteem in hysterectomized women: a mixed method approach.
Description: Effectiveness of a nursing educational intervention supported by a technological tool (Libre mujer), on quality of life, sexual function and self-esteem in hysterectomized women: a mixed method approach.
Study NCT05680558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UVADEX® (methoxsalen) Sterile Solution in conjunction with the THERAKOS® CELLEX Photopheresis
Description: Extracorporeal Photopheresis (ECP)
Study NCT04905017 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter Tricuspid Valve Replacement
Description: Replacement of the tricusupid valve using Trisol System in a transcatheter approach
Study NCT05680558 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: THERAKOS® CELLEX photopheresis system
Description: THERAKOS® CELLEX is an FDA-approved extra-corporeal photopheresis system
Study NCT05430620 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxygen
Description: Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
Study NCT05430620 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: Active oxygenation during hypothermic machine perfusion by bubble and surface oxygenation. Intermittent surface oxygenation is compared with continuous surface oxygenation during hypothermic machine perfusion
Study NCT05679414 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: RT- PCR of 2 ml EDTA blood sample to determine MTHFR C677T genotypes
Description: Venous blood sample
Study NCT06501859 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care physical therapy
Description: Standard rehabilitation protocol for 3 months.
Study NCT06501859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoulder pacemaker with physical therapy
Description: Standardized rehabilitation protocol with utilization of the shoulder pacemaker device 3 times per week over a 3-month period.
Study NCT05477186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (3 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
Study NCT05477186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (6 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
Study NCT05477186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (12 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
Study NCT05477186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (25 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
Study NCT05477186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (50 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
Study NCT05477186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (75 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
Study NCT05477186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (100 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
Study NCT05477186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (150 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
Study NCT05477186 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CV0501 (200 μg)
Description: Study vaccine will be administered as a single intramuscular injection in the deltoid area, preferably in the nondominant arm.
Study NCT06273995 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Behavioral Activation
Description: All participants will undergo behavioral activation treatment for 8-10 weeks
Study NCT05926427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Orelabrutinib
Description: 150 mg qd po, until disease progression, intolerance of drug toxicity or death, otherwise maintaining during 2 years of follow-up
Study NCT05926427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375 mg/m\^2 ivgtt, D0 of each 28-day cycle
Study NCT05926427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Not specified, recommended regimen according to histopathologic type
Study NCT06020794 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise
Description: quadriceps isometric exercises, straight leg raises, semi-squat exercises, hip flexors, hamstring and iliotibial band stretching exercises, strengthening exercises for hip abductors and adductors
Study NCT05319873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT05319873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel
Description: Given IV
Study NCT05319873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Given SC
Study NCT05319873 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Given IV
Study NCT05319873 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary Studies
Study NCT05319873 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary Studies
Study NCT05319873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib
Description: Given PO
Study NCT05319873 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given IV
Study NCT05319873 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given IV
Study NCT06020794 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: LP-PRP
Description: The LP-PRPs to be applied will be obtained by centrifugation of the venous blood taken from the patients by manual methods.
Study NCT05319873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tucatinib
Description: Given PO
Study NCT06343857 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: self-assessment questionnaire
Description: Completion of the anatomical site-specific self-assessment questionnaire.
Study NCT04761796 — intervention group
Intervention type: OTHER
Intervention: Sleeping condition self-questionnaire
Description: Professional flight members will answer a self questionnaire related to their sleeping conditions
Study NCT06119880 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancreatin Enteric-coated Capsules
Description: pancreatic enzyme replacement therapy
Study NCT06119880 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Routine treatment plan
Description: Routine treatment plan without PERT
Study NCT06077084 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Description: 4months with multimodal physiotherapy. 2 sessions/week. Sessions consisted of two sessions of 1 hour per week, focusing on neck and arm movements. Each session included education and manual therapy (20 minutes), and exercises targeting neck extensors, flexors, and shoulder girdle muscles (40 minutes).~Low-intensity neck resistance training :~Participants have to perform arm, neck flexors and extensors exercise. motor control exercises focusing on deep neck muscles, slow dynamic and static contractions (10 to 20 seconds) with low resistance using TheraBand and weights ranging from 0.5 kg to 1 kg.~High-Intensity Neck resistance training :~neck flexors exercise, neck extensors exercise, and one exercise for shoulder/upper limb. static contractions (10-seconds) and dynamic neck movements using a handheld biofeedback dynamometer or weights from 50% to 80% of the 1-repetition maximum
Study NCT04972994 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies
Description: laparoscopic intracorporeal versus extracorporeal anastomosis for right and left hemicolectomies in management of colonic cancers
Study NCT04741373 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oral nutritional supplements
Description: oral nutritional supplements, 400-600kcal/day;
Study NCT04741373 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation exercise
Description: Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week
Study NCT04741373 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: rehabilitation exercise
Description: Aerobic exercise: fixed cycling in rehabilitation center or walking at home, 3-5 times/week, Resistance exercise: lift dumbbell by upper limb, raise legs tying sandbags, 2-3 times/week
Study NCT04741373 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: health education
Description: Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
Study NCT04741373 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: health education
Description: Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
Study NCT04741373 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: health education
Description: Establish WeChat group or QQ group or telephone contact, and regularly distribute electronic science pictures or small videos
Study NCT06544278 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotic product
Description: During the experiment, subjects take one sachet probiotic product daily. Evaluation is conducted by monitoring the subjects' semen concentration before and after this trial.